These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10472089)

  • 1. [FDG-PET in oncology. Methodological principles and clinical applications].
    Kletter K; Becherer A
    Radiologe; 1999 Jul; 39(7):600-9. PubMed ID: 10472089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncological applications of FDG PET imaging.
    Delbeke D
    J Nucl Med; 1999 Oct; 40(10):1706-15. PubMed ID: 10520713
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical applications of FDG-PET in oncology.
    Czernin J
    Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
    Reske SN; Kotzerke J
    Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical role of FDG PET in evaluation of cancer patients.
    Kostakoglu L; Agress H; Goldsmith SJ
    Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography imaging in evaluation of cancer patients.
    Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
    Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
    Rigo P; Paulus P; Kaschten BJ; Hustinx R; Bury T; Jerusalem G; Benoit T; Foidart-Willems J
    Eur J Nucl Med; 1996 Dec; 23(12):1641-74. PubMed ID: 8929320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
    Hellwig D; Ukena D; Paulsen F; Bamberg M; Kirsch CM;
    Pneumologie; 2001 Aug; 55(8):367-77. PubMed ID: 11505288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET in oncology: will it replace the other modalities?
    Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
    Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Positron emission tomography (PET) with [18F]-FDG in bronchopulmonary cancer and its impact on medical decision at the time of diagnosis, staging, or recurrence evaluation].
    Grahek D; Montravers F; Mayaud C; Regnard JF; Kerrou K; Younsi N; Talbot JN
    Rev Pneumol Clin; 2001 Dec; 57(6):393-403. PubMed ID: 11924148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
    Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
    Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
    Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
    Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET/CT in oncology: "raising the bar".
    Patel CN; Goldstone AR; Chowdhury FU; Scarsbrook AF
    Clin Radiol; 2010 Jul; 65(7):522-35. PubMed ID: 20541652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
    Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
    Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.
    Johnson GR; Zhuang H; Khan J; Chiang SB; Alavi A
    Clin Nucl Med; 2003 Oct; 28(10):815-20. PubMed ID: 14508272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of FDG-PET in oncological surgery].
    Schürmann G; Franzius C; Twelker L; Senninger N; Schober O
    Chirurg; 2001 May; 72(5):528-36. PubMed ID: 11383065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.